Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Blood (2024) 144 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2024-194441

Published: 2024

Journal Articles

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 1825.

https://doi.org/10.1182/blood-2024-203274

Published: 2024

Journal Articles

A Hgb Exceeding 120g/L Does Not Increase Risk of Vascular Complications or Disease Progression in Patients with MDS Treated with Erythropoietic Stimulating Agents, a Single-Institution Retrospective Study of the MDS-CAN Registry

Clarissa Skorupski, Lisa Chodirker, Lee Mozessohn, James T England, James Kennedy, Matthew C. Cheung, Signy Chow, Jennifer Teichman, Nicola Goldberg, Samantha A. Hershenfeld, Hubert Tsui, Mohammed Siddiqui, Alexandre Mamedov, Liying Zhang, Rena Buckstein

Blood (2024) 144 (Supplement 1): 6716.

https://doi.org/10.1182/blood-2024-209053

Published: 2024

Journal Articles

Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores

Arjun Pandey, Idan Roifman, Bo Wan, Tara Williams, James Kennedy, Signy Chow, Lee Mozessohn, Lisa Chodirker, Alexandre Mamedov, Iran Rashedi, Mohammed Siddiqui, Rashmi S. Goswami, Rena Buckstein

Blood (2024) 144 (Supplement 1): 6715.

https://doi.org/10.1182/blood-2024-208203

Published: 2024

Journal Articles

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Blood (2024) 144 (Supplement 1): 4598.

https://doi.org/10.1182/blood-2024-211183

Published: 2024

Journal Articles

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

Blood (2024) 144 (Supplement 1): 3228.1.

https://doi.org/10.1182/blood-2024-200797

Published: 2024

Journal Articles

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Rena Buckstein, Olivia Lopes, Amy J. M. McNaughton, Matthew C. Cheung, Lee Mozessohn, Lisa Chodirker, Kevin Imrie, Neil Berinstein, Signy Chow, Gillian Kupakuwana-Suk, Anne Parmentier, Prasha Sasitharakumar, Hubert Tsui, Liying Zhang, Michael J. Rauh

Blood (2023) 142 (Supplement 1): 442.

https://doi.org/10.1182/blood-2023-187778

Published: 2023

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Troy Climans, Camilla Zimmermann, Annette E. Hay, Harriet Richardson, Pierre Villeneuve, Lee Mozessohn, Andre C. Schuh, Janique Dyba, Breffni Hannon, David Lee, Rena Buckstein, Argin Malakian, Kyle Fitzgibbon, Joel Lefebvre, Wei Tu, Gary Rodin

Blood (2023) 142 (Supplement 1): 1494.

https://doi.org/10.1182/blood-2023-174378

Published: 2023

Journal Articles

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

Valeria Santini, Rami S. Komrokji, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Karen L. Keeperman, Shelonitda Rose, Ana Carolina Giuseppi, Valerie Vilmont, Yinzhi Lai, Dimana Miteva, Barkha Aggarwal, Uwe Platzbecker, Pierre Fenaux, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 915.

https://doi.org/10.1182/blood-2023-178546

Published: 2023

Journal Articles

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Valeria Santini, Shelonitda Rose, Priya Malini, Glen Lew, Dimple Aggarwal, Karen L. Keeperman, Huijing Jiang, Ana Carolina Giuseppi, Jennie Zhang, Thomas Cluzeau, Jake Shortt, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 6503.

https://doi.org/10.1182/blood-2023-178635

Published: 2023

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment

Signy Chow, Alexandra Misura, Olga Bigun, Sila Usta, Renato Sasso, Dylan Gowlett-Park, Katarina Czibere, Rena Buckstein, Lee Mozessohn, Lisa Chodirker, James Kennedy, Hubert Tsui

Blood (2023) 142 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2023-188464

Published: 2023

Journal Articles

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Blood (2023) 141 (17): 2047–2061.

https://doi.org/10.1182/blood.2022018604

Published: 2023

Includes: Supplemental data

Journal Articles

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Blood (2022) 140 (20): 2170–2174.

https://doi.org/10.1182/blood.2022016171

Published: 2022

Includes: Supplemental data

Journal Articles

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Neelan Sriranjan, Anna R. Blankstein, Nora Choi, Kristjan Paulson, David Sanford, Lee Mozessohn, Donald S. Houston, Emily Rimmer, Sylvain Lother, Asher Mendelson, Allan Garland, Rena Buckstein, Annette E. Hay, Ryan Zarychanski, Brett L. Houston

Blood (2022) 140 (Supplement 1): 11632–11633.

https://doi.org/10.1182/blood-2022-171047

Published: 2022

Journal Articles

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Dimana Miteva, Pierre Fenaux

Blood (2022) 140 (Supplement 1): 6971–6973.

https://doi.org/10.1182/blood-2022-157487

Published: 2022

Journal Articles

Chromatin Architecture Protein CTCF Plays a Role in Determining 5-Azacytidine Response of Leukemic Cells By Potentially Regulating Hoxb Genes

Aparna Gopal, Derek Tam, Ryan J. Stubbins, Kieran O'Neill, Marion Shadbolt, Deborah Deng, Rena Buckstein, Aly Karsan

Blood (2022) 140 (Supplement 1): 5850–5851.

https://doi.org/10.1182/blood-2022-170674

Published: 2022

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

NARROW

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Improvement in Quality of Life in MDS Patients Who Become Transfusion Independent after Treatment

Improvements in Hematological Parameters and Quality of Life (QOL) with Elritercept (KER-050): Results from an Ongoing Phase 2 Trial in Participants with Lower-Risk (LR) Myelodysplastic Neoplasms (MDS)

A Hgb Exceeding 120g/L Does Not Increase Risk of Vascular Complications or Disease Progression in Patients with MDS Treated with Erythropoietic Stimulating Agents, a Single-Institution Retrospective Study of the MDS-CAN Registry

Mutational and Clinical Characteristics Associated with Atherosclerotic Disease Burden in the MDS Canada Database: A Single-Center Analysis of CT Coronary Artery Calcium Scores

Impact of Frailty in a Prospective Cohort of Patients with MDS Treated with Hypomethylating Agents

Renew Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Neoplasms (MDS)

The Impact of Clonal Hematopoiesis on Clinical Outcomes and Clonal Dynamics in Older Lymphoma Patients Receiving Chemotherapy

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)-Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study

The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes

Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML-MRC) Receiving Intensive Vs. Non-Intensive First Line Treatment

Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

Evaluation of Bleeding and Thrombocytopenia in Older Adults with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review and Meta-Analysis

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Chromatin Architecture Protein CTCF Plays a Role in Determining 5-Azacytidine Response of Leukemic Cells By Potentially Regulating Hoxb Genes

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only